Ritu Pandey, PhD

Associate Research Professor, Cellular and Molecular Medicine

Associate Director, Translational Clinical Bioinformatics, CB2, UAHS

ritu@email.arizona.edu

Cancer Focus

Data driven research. Our interest is to investigate underlying molecular events in patient cohorts by integrated computational analysis of clinical and molecular data from multi-omics projects. Translate the datasets into insights that advance understanding of biomarkers/therapeutic targets and response to treatment.

Research Program Role

Clinical and Translational Oncology Program

Display Name

Ritu Pandey, PhD

Publications

Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers

Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, et al. 2024. Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers. Molecular Therapy: Oncology. 32(1):200786.

Gene Expression Patterns Associated with Survival in Glioblastoma

Morrison C, Weterings E, Gravbrot N, Hammer M, Weinand M, Sanan A, Pandey R, Mahadevan D, Stea B. 2024. Gene Expression Patterns Associated with Survival in Glioblastoma. International Journal of Molecular Sciences. 25(7):3668.

High-fat diet plus HNF1A variant promotes polyps by activating β-catenin in early-onset colorectal cancer

Song H, Sontz RA, Vance MJ, Morris JM, Sheriff S, Zhu S, Duan S, Zeng J, Koeppe E, Pandey R, et al. 2023. High-fat diet plus HNF1A variant promotes polyps by activating β-catenin in early-onset colorectal cancer. JCI Insight. 8(13).

Clear cell renal cell carcinoma molecular variations in <scp>non‐Hispanic</scp> White and Hispanic patients

Batai K, Chen Y, Rheinheimer BA, Arora A, Pandey R, Heimark RL, Bracamonte ER, Ellis NA, Lee BR. 2023. Clear cell renal cell carcinoma molecular variations in <scp>non‐Hispanic</scp> White and Hispanic patients. Cancer Medicine. 12(11):12792–12801.

Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing’s Disease

Chakrabarti J, Pandey R, Churko JM, Eschbacher J, Mallick S, Chen Y, Hermes B, Mallick P, Stansfield BN, Pond KW, et al. 2022. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing’s Disease. Cells. 11(21):3344.

Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival.

Wusterbarth E, Chen Y, Jecius H, Krall E, Runyan RB, Pandey R, Nfonsam V. 2022. Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival. J Surg Res. 270:169–177. doi:10.1016/j.jss.2021.09.007.

A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression.

Cheng JN, Frye JB, Whitman SA, Kunihiro AG, Pandey R, Funk JL. 2021. A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression. Int J Mol Sci. 22. doi:10.3390/ijms22094463.

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients.

Pandey R, Johnson N, Cooke L, Johnson B, Chen Y, Pandey M, Chandler J, Mahadevan D. 2021. TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients. Cancers (Basel). 13. doi:10.3390/cancers13040597.

Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.

Pandey R, Zhou M, Chen Y, Darmoul D, Kisiel CC, Nfonsam VN, Ignatenko NA. 2021. Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. Genes (Basel). 12. doi:10.3390/genes12050749.

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.

Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, et al. 2021. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 12:7349. doi:10.1038/s41467-021-26901-9.

PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.

Singh N, Padi SKR, Bearss JJ, Pandey R, Okumura K, Beltran H, Song JH, Kraft AS, Olive V. 2020. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 14:974–990. doi:10.1002/1878-0261.12662.

A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes.

Larson K, Kannaiyan R, Pandey R, Chen Y, Babiker HM, Mahadevan D. 2020. A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes. Cancers (Basel). 12. doi:10.3390/cancers12030701.

Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma.

Segar JM, Pandey R, Farr KJ, Nagle R, LeBeau L, Gonzalez VJ, Chalasani P. 2020. Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma. Int J Breast Cancer. 2020:8816824. doi:10.1155/2020/8816824.

Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.

Pandey R, Zhou M, Islam S, Chen B, Barker NK, Langlais P, Srivastava A, Luo M, Cooke LS, Weterings E, et al. 2019. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Sci Rep. 9:18347. doi:10.1038/s41598-019-54545-9.

Kallikrein 6 protease advances colon tumorigenesis induction of the high mobility group A2 protein.

Chen H, Sells E, Pandey R, Abril ER, Hsu C-H, Krouse RS, Nagle RB, Pampalakis G, Sotiropoulou G, Ignatenko NA. 2019. Kallikrein 6 protease advances colon tumorigenesis induction of the high mobility group A2 protein. Oncotarget. 10:6062–6078. doi:10.18632/oncotarget.27153.

Circulating miRNA Profiling of Women at High Risk for Ovarian Cancer.

Pandey R, Woo H-H, Varghese F, Zhou M, Chambers SK. 2019. Circulating miRNA Profiling of Women at High Risk for Ovarian Cancer. Transl Oncol. 12:714–725. doi:10.1016/j.tranon.2019.01.006.

Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death.

Song JH, Kang H-J, Luevano LA, Gokhale V, Wu K, Pandey R, Chow H-HS, Hurley LH, Kraft AS. 2019 May. Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chem Biol. doi:10.1016/j.chembiol.2019.04.009.

Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.

Sells E, Pandey R, Chen H, Skovan BA, Cui H, Ignatenko NA. 2017. Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6. Neoplasia. 19:396–411. doi:10.1016/j.neo.2017.02.003.

Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.

Padi SKR, Luevano LA, An N, Pandey R, Singh N, Song JH, Aster JC, Yu X-Z, Mehrotra S, Kraft AS. 2017. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 8:30199–30216. doi:10.18632/oncotarget.16320.

Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migration.

Greenwood E, Maisel S, Ebertz D, Russ A, Pandey R, Schroeder J. 2016. Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migration. Oncotarget. 7:60776–60792. doi:10.18632/oncotarget.11320.

Ritu Pandey, PhD

Cancer Focus

Display Name Ritu Pandey, PhD

Publications

Display Name

Ritu Pandey, PhD